At present, there are still insufficient evidence and studies about the combination of chemotherapy with the other JNK and p38 MAPK inhibitors to make conclusions of their combinatory effects for NPC treatment. The gene discussed is MAPK1; the disease is nasopharyngeal carcinoma.